hiPSC modeling of inherited cardiomyopathies

Current Treatment Options in Cardiovascular Medicine

Volumn 16, Issue 7, 2014, Pages

  Jung, Gwanghyun ^a   Bernstein, Daniel ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Arrhythmia; Cardiomyocytes; Contractility; Development; Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Induced pluripotent stem cells; Stem cells

Indexed keywords

ALPHA ACTININ; FRATAXIN; GAP JUNCTION PROTEIN; ISOPRENALINE; MYOSIN HEAVY CHAIN BETA; PROPRANOLOL; RYANODINE; TROPONIN T;

BARTH SYNDROME; CARDIOMYOPATHY; CELL ULTRASTRUCTURE; CONGESTIVE CARDIOMYOPATHY; FAMILIAL DISEASE; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; GLYCOGEN STORAGE DISEASE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MISSENSE MUTATION; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; POINT MUTATION; PULMONARY VALVE STENOSIS; REVIEW; SCREENING; TREATMENT OUTCOME;

EID: 84901519728     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-014-0320-7     Document Type: Review

References (49)

1. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363:1397-409.
2. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471:230-4.
3. Ma D, Wei H, Lu J, Ho S, Zhang G, Sun X, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2013;34:1122-33.
4. •• Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4:130ra47. This study describes the first successful modeling of dilated cardiomyopathy in hiPSC-CMs. Familial dilated cardiomyopathy with inherited mutation in troponin T was recapitulated in vitro showing impaired contraction.
5. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12:101-13.
6. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465:808-12.
7. •• Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-72. This is one of the ground-breaking reports from Shinya Yamanaka's group demonstrating the ability to reprogram adult human cells into pluripotent stem cells, ultimately leading to his receiving the Nobel Prize in Physiology or Medicine along with John Gurdon in 2012.
8. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
9. Denning C, Anderson D. Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discov Today Ther Strateg. 2008;5:223-32.
10. Merkle FT, Eggan K. Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell. 2013;12:656-68.
11. •• Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127:1677-91. Using a collection of hiPSC-CMs from patients with inheried cardiac disorders, this study demonstrated patient-specific differential drug activity and drug cardiotoxicity, suggesting the possibility of using hiPSC-CMs for personalized drug screening.
12. Siu CW, Lee YK, Ho JC, Lai WH, Chan YC, Ng KM, et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging. 2012;4:803-22.
13. Tse HF, Ho JC, Choi SW, Lee YK, Butler AW, Ng KM, et al. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. Hum Mol Genet. 2013;22:1395-403.
14. Hick A, Wattenhofer-Donze M, Chintawar S, Tropel P, Simard JP, Vaucamps N, et al. Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia. Dis Model Mech. 2013;6:608-21.
15. Dudek J, Cheng IF, Balleininger M, Vaz FM, Streckfuss-Bomeke K, Hubscher D, et al. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome. Stem Cell Res. 2013;11:806-19.
16. Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies. Nat Med. 2014;in press.
17. Huang HP, Chen PH, Hwu WL, Chuang CY, Chien YH, Stone L, et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet. 2011;20:4851-64.
18. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98:1329-34. (Pubitemid 28443398)
19. Wu CF, Bishopric NH, Pratt RE. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem. 1997;272:14860-6. (Pubitemid 27251756)
20. Snopko RM, Ramos-Franco J, Di Maio A, Karko KL, Manley C, Piedras-Renteria E, et al. Ca2+ sparks and cellular distribution of ryanodine receptors in developing cardiomyocytes from rat. J Mol Cell Cardiol. 2008;44:1032-44.
21. Gherghiceanu M, Barad L, Novak A, Reiter I, Itskovitz-Eldor J, Binah O, et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. J Cell Mol Med. 2011;15:2539-51.
22. Snir M, Kehat I, Gepstein A, Coleman R, Itskovitz-Eldor J, Livne E, et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol. 2003;285:H2355-63. (Pubitemid 37443051)
23. Lieu DK, Liu J, Siu CW, McNerney GP, Tse HF, Abu- Khalil A, et al. Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev. 2009;18:1493-500.
24. Baharvand H, Ashtiani SK, Valojerdi MR, Shahverdi A, Taee A, Sabour D. Establishment and in vitro differentiation of a new embryonic stem cell line from human blastocyst. Differ Res Biol Divers. 2004;72:224-9. (Pubitemid 41702131)
25. Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell. 2009;5:434-41.
26. Yamada KA, Rogers JG, Sundset R, Steinberg TH, Saffitz J. Up-regulation of connexin45 in heart failure. J Cardiovasc Electrophysiol. 2003;14:1205-12. (Pubitemid 37452891)
27. Blazeski A, Zhu R, Hunter DW, Weinberg SH, Zambidis ET, Tung L. Cardiomyocytes derived from human induced pluripotent stem cells asmodels for normal and diseased cardiac electrophysiology and contractility. Prog Biophys Mol Biol. 2012;110:166-77.
28. Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010;4:107-16.
29. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral en-doderm- like cells. Circulation. 2003;107:2733-40. (Pubitemid 36667249)
30. de Sousa C, Lopes SM, Hassink RJ. Feijen A, van Rooijen MA, Doevendans PA, Tertoolen L, et al. Patterning the heart, a template for human cardiomyocyte development. Dev Dyn Off Publ Am Assoc Anat. 2006;235:1994-2002. (Pubitemid 43902356)
31. Germanguz I, Sedan O, Zeevi-Levin N, Shtrichman R, Barak E, Ziskind A, et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J Cell Mol Med. 2011;15:38-51.
32. Satin J, Itzhaki I, Rapoport S, Schroder EA, Izu L, Arbel G, et al. Calcium handling in human embryonic stem cell-derived cardiomyocytes. Stem Cells. 2008;26:1961-72.
33. Ziman AP, Gomez-Viquez NL, Bloch RJ, Lederer WJ. Excitation-contraction coupling changes during postnatal cardiac development. J Mol Cell Cardiol. 2010;48:379-86.
34. Zhang GQ, Wei H, Lu J, Wong P, Shim W. Identification and characterization of calcium sparks in cardiomyocytes derived from human induced pluripotent stem cells. PLoS One. 2013;8:e55266.
35. Fujiwara M, Yan P, Otsuji TG, Narazaki G, Uosaki H, Fukushima H, et al. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One. 2011;6:e16734.
36. Novak A, Barad L, Zeevi-Levin N, Shick R, Shtrichman R, Lorber A, et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation. J Cell Mol Med. 2012;16:468-82.
37. Pillekamp F, Haustein M, Khalil M, Emmelheinz M, Nazzal R, Adelmann R, et al. Contractile properties of early human embryonic stem cell-derived cardiomyocytes: beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev. 2012;21:2111-21.
38. Norman JJ, Mukundan V, Bernstein D, Pruitt BL. Microsystems for biomechanical measurements. Pediatr Res. 2008;63:576-83. (Pubitemid 351572229)
39. Liu J, Sun N, Bruce MA, Wu JC, Butte MJ. Atomic force mechanobiology of pluripotent stem cell-derived cardiomyocytes. PLoS One. 2012;7:e37559.
40. Taylor RE, Kim K, Sun N, Park SJ, Sim JY, Fajardo G, et al. Sacrificial layer technique for axial force post assay of immature cardiomyocytes. Biomed Microdevices. 2013;15:171-81.
41. Burridge PW, Thompson S, Millrod MA, Weinberg S, Yuan X, Peters A, et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS ONE. 2011;6:e18293.
42. White MP, Rufaihah AJ, Liu L, Ghebremariam YT, Ivey KN, Cooke JP, et al. Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells. Stem Cells. 2013;31:92-103.
43. •• Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 2013;12:127-37. Increasing the purity of differentiated cardiomyocytes in vitro is a key issue for furthering the field of hiPSC-CM research. These authors demonstrated improvement of cardiomyocyte sorting based on differences in glucose and lactate metabolism, yielding cardiomyocyte populations of extremely high purity.
44. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. Nature. 2010;467:285-90.
45. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol. 2010;28:848-55.
46. Rao C, Prodromakis T, Kolker L, Chaudhry UA, Trantidou T, Sridhar A, et al. The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials. 2013;34:2399-411.
47. Chan YC, Ting S, Lee YK, Ng KM, Zhang J, Chen Z, et al. Electrical stimulation promotes maturation of cardiomyocytes derived from human embryonic stem cells. J Cardiovasc Transl Res. 2013;6:989-99.
48. Lundy SD, Zhu WZ, Regnier M, Laflamme MA. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013;22:1991-2002.
49. •• Dambrot C, Passier R, Atsma D, Mummery CL. Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochem J. 2011;434:25-35. This review article, from one of the leaders in the field, provides a well-written, comprehensive review of stem cell techniques useful in cardiovascular research.